Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (NCT05533697)

🧪 Interventions in This Study

• mRNA-4359 (BIOLOGICAL)
• Pembrolizumab (BIOLOGICAL)
• Ipilimumab (BIOLOGICAL)
• Nivolumab (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (39 Sites)

Showing the first 25 of 39 sites.

• The Angeles Clinic and Research Institute — Los Angeles, California
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
• University of Colorado Cancer Center — Aurora, Colorado
• George Washington University — Washington D.C., District of Columbia
• Orlando Health UF Health Cancer Center — Orlando, Florida
• The University of Chicago Medicine — Chicago, Illinois
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• Henry Ford Hospital — Detroit, Michigan
• Washington University — St Louis, Missouri
• John Theurer Cancer Center — Hackensack, New Jersey
• NYU Langone Health-Perlmutter Cancer Center — New York, New York
• Memorial Sloan Kettering Cancer Center - Melanoma & Immunotherapeutics — New York, New York
• Carolina BioOncology Institute — Huntersville, North Carolina
• Oregon Health & Science University — Portland, Oregon
• Sara Cannon Research Institute Tennessee — Nashville, Tennessee
• Southside Cancer Center — Miranda, New South Wales
• Wollongong Hospital — Wollongong, New South Wales
• Melanoma Institute Australia — Wollstonecraft, New South Wales
• Austin Hospital — Melbourne, Victoria
• One Clinical Research — Nedlands, Western Australia
• Lungenfachklinik Immenhausen - Thoracic Oncology — Immenhausen, Hesse
• A.O. Santa Maria della Misericordia — Udine, Perugia
• Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie — Warsaw, Masovia
• South Texas Accelerated Research Therapeutics (START) - Rioja — Logroño, La Rioja

📞 Contact the Study Coordinator

Phone: (866) 663-3762

Email: WeCareClinicalTrials@modernatx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumors

• A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
• A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
• QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
• A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
• A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
• A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California

Explore by condition: All Advanced Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.